Ivo Schmerold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ivo Schmerold has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Romeo Teodor Cristina
Department of Pharmacology and Pharmacy, University of Life Sciences “King Mihai I” from Timișoara, Calea Aradului 119, 300645 Timișoara, Romania
2 shared publications - Agnes Dadak
Institute of Pharmacology and Toxicology, Clinical Pharmacology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
1 shared publication - Diana Obistioiu
Faculty of Agriculture, University of Life Sciences “King Mihai I” from Timisoara, Calea Aradului 119, 300645 Timisoara, Romania
1 shared publication E. Tyden
Division of Parasitology, Department of Biomedical Science and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden
1 shared publicationH. Linden
Veddesta Business Center, EUFEPS, Järfälla (Stockholm), Sweden
1 shared publicationHans Niedermüller
Institute of Physiology and Ludwig Boltzmann Institute for Aging Research, Department of Natural Sciences, Veterinary University of Vienna, Vienna, Austria
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 21 May 2023
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 189, 106473
European regulations on the use of antibiotics in veterinary medicine
- 21 May 2023
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 189, 106473
Top Cited PapersOpen AccessEuropean regulations on the use of antibiotics in veterinary medicine
- Open Access
- 20 December 2017
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 41 (3) , 378-383
Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences
The European Federation for Pharmaceutical Sciences (EUFEPS) was founded 25 years ago by more than 20 national pharmaceutical societies and faculty members. As a pan‐European organization, it brings together pharmaceutical societies as well as academic, industrial and regulatory scientists engaged in drug research and development, drug regulation and education of professionals working in these fields. EUFEPS represents pharmaceutical sciences in Europe and is recognized as such by both the European Commission and the European Medicines Agency. EUFEPS cooperates with the European Federation of Pharmaceutical Industries and other European organizations and maintains global connections with agencies such as the US Food and Drug Administration and the American Association of Pharmaceutical Scientists. EUFEPS has established specified networks forming the basis of its activities. The creation of a Network on Veterinary Medicines is prompted by the manifold problems resulting from the use of veterinary drugs and its inherent interconnections with human medicine, environmental and public health. A long‐term goal of this initiative was to expand the spectrum of available therapeutics for use in animals, including the development of innovative delivery systems.
- 20 December 2017
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 41 (3) , 378-383
Open AccessNetwork on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences
The European Federation for Pharmaceutical Sciences (EUFEPS) was founded 25 years ago by more than 20 national pharmaceutical societies and faculty members. As a pan‐European organization, it brings together pharmaceutical societies as well as academic, industrial and regulatory scientists engaged in drug research and development, drug regulation and education of professionals working in these fields. EUFEPS represents pharmaceutical sciences in Europe and is recognized as such by both the European Commission and the European Medicines Agency. EUFEPS cooperates with the European Federation of Pharmaceutical Industries and other European organizations and maintains global connections with agencies such as the US Food and Drug Administration and the American Association of Pharmaceutical Scientists. EUFEPS has established specified networks forming the basis of its activities. The creation of a Network on Veterinary Medicines is prompted by the manifold problems resulting from the use of veterinary drugs and its inherent interconnections with human medicine, environmental and public health. A long‐term goal of this initiative was to expand the spectrum of available therapeutics for use in animals, including the development of innovative delivery systems.
- Open Access
- 29 January 2014
- Published by Springer Nature in BMC Chemistry
- Vol. 8 (1) , 6
Chemical characterization by GC-MS and in vitro activity against Candida albicans of volatile fractions prepared from Artemisia dracunculus, Artemisia abrotanum, Artemisia absinthium and Artemisia vulgaris
Background: A large number of essential oils is reported to have significant activity againstCandida albicans. But the different chemical composition influences the degree of their activity. The intention of this study was to investigate the chemical composition and the activity againstCandida albicansof volatile oils obtained fromArtemisia dracunculus,A. abrotanum,A. absinthiumandA. vulgaris(Asteraceae). The aim of the study was to identify new chemical compounds that have effect againstC. albicans.The essential oils were obtained by hydrodistillation or extraction with dichloromethane (a new procedure we developed trying to obtain better, more separated compounds) from air dried above ground plant material and analyzed by GC-MS. Additionally commercial essential oils from the same species were tested. TheCandida albicansinhibition studies were carried out by the paper disc diffusion method.Results: The essential oils shared common components but presented differences in composition and showed variable antifungal activity. Davanone and derivatives thereof, compounds with silphiperfolane skeleton, estragole, davanone oil, β-thujone, sabinyl acetate, herniarin, cis-chrysanthenyl acetate, 1,8-cineol, and terpineol were the main components ofArtemisiavolatiles.Conclusions: Among the volatile fractions tested those fromA. abrotanumcontaining davanone or silphiperfolane derivatives showed the highest antifungal activity. Thein vitrotests revealed that theArtemisiaoils are promising candidates for further research to develop novel anti-candida drugs.
- 29 January 2014
- Published by Springer Nature in BMC Chemistry
- Vol. 8 (1) , 6
Open AccessChemical characterization by GC-MS and in vitro activity against Candida albicans of volatile fractions prepared from Artemisia dracunculus, Artemisia abrotanum, Artemisia absinthium and Artemisia vulgaris
Background: A large number of essential oils is reported to have significant activity againstCandida albicans. But the different chemical composition influences the degree of their activity. The intention of this study was to investigate the chemical composition and the activity againstCandida albicansof volatile oils obtained fromArtemisia dracunculus,A. abrotanum,A. absinthiumandA. vulgaris(Asteraceae). The aim of the study was to identify new chemical compounds that have effect againstC. albicans.The essential oils were obtained by hydrodistillation or extraction with dichloromethane (a new procedure we developed trying to obtain better, more separated compounds) from air dried above ground plant material and analyzed by GC-MS. Additionally commercial essential oils from the same species were tested. TheCandida albicansinhibition studies were carried out by the paper disc diffusion method.Results: The essential oils shared common components but presented differences in composition and showed variable antifungal activity. Davanone and derivatives thereof, compounds with silphiperfolane skeleton, estragole, davanone oil, β-thujone, sabinyl acetate, herniarin, cis-chrysanthenyl acetate, 1,8-cineol, and terpineol were the main components ofArtemisiavolatiles.Conclusions: Among the volatile fractions tested those fromA. abrotanumcontaining davanone or silphiperfolane derivatives showed the highest antifungal activity. Thein vitrotests revealed that theArtemisiaoils are promising candidates for further research to develop novel anti-candida drugs.
- 19 April 2005
- Published by Springer Nature in Virchows Archiv
- Vol. 446 (6) , 634-639
Low dose magnetic fields do not cause oxidative DNA damage in human placental cotyledons in vitro
The biological impact of low dose magnetic fields generated by electric appliances present in the human environment is still uncertain. In this study, human placentas served as a model tissue for the evaluation of the potential effect of oscillating low intensity magnetic fields on the concentration of 8-hydroxy-2′-deoxyguanosine (8-OH-dG) in cellular DNA. Cotyledons were dissected from placentas obtained immediately after physiological labours and exposed to magnetic fields (groups MF A, 2 mT, 50 Hz and MF B, 5 mT, 50 Hz) or sham exposed (group C) during an in vitro perfusion of 3 h. Cellular DNA was isolated, hydrolyzed and analyzed by HPLC. Native nucleosides were monitored at 254 nm and 8-OH-dG by electrochemical detection. Results were expressed as μmol 8-OH-dG/mol deoxyguanosine (dG). The concentrations of 8-OH-dG in group C, MF A and MF B were 28.45±15.27 μmol/mol dG, 62.80±31.91 μmol/mol dG, and 27.49±14.23 μmol/mol dG, respectively, demonstrating no significant difference between the groups. The results suggest that placental tissues possess a capacity to protect DNA against oxidative alterations by magnetic field of intensities previously shown to produce radical mediated DNA damage in rat brain cells in vivo and imbalances in electrolyte release of cotyledons under in vitro conditions.
- 19 April 2005
- Published by Springer Nature in Virchows Archiv
- Vol. 446 (6) , 634-639
Low dose magnetic fields do not cause oxidative DNA damage in human placental cotyledons in vitro
The biological impact of low dose magnetic fields generated by electric appliances present in the human environment is still uncertain. In this study, human placentas served as a model tissue for the evaluation of the potential effect of oscillating low intensity magnetic fields on the concentration of 8-hydroxy-2′-deoxyguanosine (8-OH-dG) in cellular DNA. Cotyledons were dissected from placentas obtained immediately after physiological labours and exposed to magnetic fields (groups MF A, 2 mT, 50 Hz and MF B, 5 mT, 50 Hz) or sham exposed (group C) during an in vitro perfusion of 3 h. Cellular DNA was isolated, hydrolyzed and analyzed by HPLC. Native nucleosides were monitored at 254 nm and 8-OH-dG by electrochemical detection. Results were expressed as μmol 8-OH-dG/mol deoxyguanosine (dG). The concentrations of 8-OH-dG in group C, MF A and MF B were 28.45±15.27 μmol/mol dG, 62.80±31.91 μmol/mol dG, and 27.49±14.23 μmol/mol dG, respectively, demonstrating no significant difference between the groups. The results suggest that placental tissues possess a capacity to protect DNA against oxidative alterations by magnetic field of intensities previously shown to produce radical mediated DNA damage in rat brain cells in vivo and imbalances in electrolyte release of cotyledons under in vitro conditions.